Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/31/2023* -- Results Q4 2022 -- -0.12 --
08/15/2022 -- Results Q2 2022 -0.09 -0.07 -30.29%
05/16/2022 -- Results Q1 2022 -0.06 -0.09 33.22%
03/31/2022 -- Results Q4 2021 -0.12 -0.09 -28.53%
11/15/2021 -- Results Q3 2021 -0.08 -0.08 -1.84%
08/17/2021 -- Results Q2 2021 -0.07 -0.08 13.60%
05/18/2021 -- Results Q1 2021 -0.08 -0.09 7.70%
03/31/2021 -- Results Q4 2020 -0.07 -0.07 6.45%
*Estimated Date/Time

Earnings

Next Report Date 03/31/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/15/2022
Beat/Miss Upgrade
Return Since -42.69%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
URL https://www.aimimmuno.com
Investor Relations URL http://ir.hemispherx.net/
HQ State/Province Florida
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 31, 2023 (est.)
Last Earnings Release Aug. 15, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-67.80%
-28.59%
-49.84%
-47.69%
-93.17%
229.0%
-48.60%
-51.09%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-14.29%
-44.57%
-56.37%
48.58%
-52.96%
5.47%
10.67%
-77.09%
43.68%
-61.17%
-88.94%
-77.05%
-79.57%
12.53%
-8.16%
83.59%
-63.32%
14.36%
-9.25%
-20.87%
-26.99%
71.01%
-21.87%
1.26%
-12.73%
-15.13%
-38.66%
-22.43%
64.36%
-57.25%
115.9%
85.91%
-11.34%
As of November 25, 2022.

Profile

Edit
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
URL https://www.aimimmuno.com
Investor Relations URL http://ir.hemispherx.net/
HQ State/Province Florida
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 31, 2023 (est.)
Last Earnings Release Aug. 15, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter AIM Tweets